These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8311080)

  • 1. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Delmez JA
    Am J Kidney Dis; 1994 Feb; 23(2):229-36. PubMed ID: 8311080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy.
    Rodriguez M; Felsenfeld AJ; Llach F
    Kidney Int; 1991 Dec; 40(6):1063-8. PubMed ID: 1762307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Brown A; Dusso A
    Kidney Int Suppl; 1999 Dec; 73():S14-9. PubMed ID: 10633458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol.
    Rodriguez M; Martin-Malo A; Martinez ME; Torres A; Felsenfeld AJ; Llach F
    Kidney Int; 1991 Dec; 40(6):1055-62. PubMed ID: 1762306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure.
    Slatopolsky E; Dusso A; Brown AJ
    Am J Med Sci; 1999 Jun; 317(6):370-6. PubMed ID: 10372836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus.
    Bover J; Jara A; Trinidad P; Rodriguez M; Felsenfeld AJ
    Bone; 1999 Sep; 25(3):279-85. PubMed ID: 10495131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Delmez JA
    Nephrol Dial Transplant; 1996; 11 Suppl 3():130-5. PubMed ID: 8840328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent of suppress toxic hyperparathyroidism.
    Nagode LA; Chew DJ; Podell M
    Vet Clin North Am Small Anim Pract; 1996 Nov; 26(6):1293-330. PubMed ID: 8911021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
    Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
    Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
    Slatopolsky E; Finch J; Ritter C; Takahashi F
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
    Brown AJ; Zhong M; Finch J; Ritter C; Slatopolsky E
    Endocrinology; 1995 Apr; 136(4):1419-25. PubMed ID: 7895652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of parathyroid hormone synthesis in chronic renal failure in rats.
    Fukagawa M; Kaname S; Igarashi T; Ogata E; Kurokawa K
    Kidney Int; 1991 May; 39(5):874-81. PubMed ID: 2067203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
    Funahashi H; Tanaka Y; Imai T; Wada M; Tsukamura K; Hayakawa Y; Matsuura N; Kikumori T; Oiwa M; Tominaga Y; Takagi H
    J Endocrinol Invest; 1998 Jan; 21(1):43-7. PubMed ID: 9633022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
    Denda M; Finch J; Slatopolsky E
    Am J Kidney Dis; 1996 Oct; 28(4):596-602. PubMed ID: 8840952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.